cilengitide Report issue

Biologics Peptide Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis, and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation.   Wikipedia

Chemistry

  • SMILES: CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC1=O
  • InChIKey: AMLYAMJWYAIXIA-VWNVYAMZSA-N
  • Mol. Mass: 588.67
  • ALogP: -2.18
  • ChEMBL Molecule:
    cilengitide  
More Chemistry

Pharmacology

Alternative names

cilengitide | cyclic-arg-gly-asp-d-phe(n-methyl)val | cyclo(arginyl-glycyl-formylaspartyl-n-methylvalyl) | cyclo(rgdf-n(me)v) | emd-12192 | emd121974 | emd 121974 | emd-121974

Organizations (26)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (51)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (51)


 

Astrocytoma (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 1)

Breast Neoplasms, Male (Phase 1)

Burkitt Lymphoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Choroid Plexus Neoplasms (Phase 1)

Craniopharyngioma (Phase 1)

Diffuse Intrinsic Pontine Glioma (Phase 1)

DNA Mismatch Repair (Phase 1)

Ependymoma (Phase 1)

Glioblastoma (Phase 3)

Glioma (Phase 2)

Gliosarcoma (Phase 2)

Hodgkin Disease (Phase 1)

Intestinal Neoplasms (Phase 1)

Intraocular Lymphoma (Phase 1)

Kidney Failure, Chronic (Phase 1)

Leukemia (Phase 2)

Leukemia, Eosinophilic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, AIDS-Related (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Anaplastic (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 1)

Medulloblastoma (Phase 1)

Melanoma (Phase 2)

Meningioma (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Germ Cell and Embryonal (Phase 1)

Neoplasms, Squamous Cell (Phase 1/Phase 2)

Neuroectodermal Tumors (Phase 1)

Oligodendroglioma (Phase 2)

Precancerous Conditions (Phase 1)

Sarcoma (Phase 1)

Sezary Syndrome (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue